Design Template
17-18 November 2014 | Marriott Grosvenor
8:15 am - 9:00 amRegistration and Refreshments
9:00 am - 9:05 amOpening Remarks from the Chair

Andrew Ward, Pharmaceuticals Correspondent, Financial Times

9:05 am - 10:05 amView from the Top: The Life Science Industry in the New Health Economy 2020

Bahija Jallal, Executive Vice President, AstraZeneca, Head, MedImmune
Dr Flemming Ornskov, Chief Executive Officer, Shire
Hanno Ronte, Partner, Monitor Deloitte
Rob ten HoedtExecutive Vice President and President EMEA & Canada, Medtronic; Chairman, Eucomed
Brent Saunders, CEO and President, Actavis

The global life science industry is undergoing a period of profound structural change. Convergence is taking place along the entirety of the value chain with the blurring of boundaries between pharma, diagnostics, biotech, medical devices and generics. Meanwhile the industry is expanding it boundaries through innovative new collaborations with payers and patients, and with many non-traditional players from the world of retail consumer and big data. Increasingly the industry also finds itself competing with some of these same players for a stake in the new health economy. What will the life science company of 2020 look like? Who will be the new competition? Will we see more consolidation or fragmentation in the industry? Will we see companies focussed on particular therapeutic areas? How will the relationship between pharma and biotech evolve? 

10:05 am - 10:30 amNetworking Coffee Break
10:30 am - 11:10 amFit for the Future? Regulation for the New Life Sciences Era

Dr Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency (EMA)
Sir Andrew Dillon, Chief Executive, National Institute for Health and Care Excellence (NICE)
Michael Doherty, Global Head, Pharma Regulatory Affairs, Hoffmann La- Roche

A frequent criticism directed at the industry regulators is their tardiness in keeping up with the pace of scientific innovation and ‘overzealous’ regulation deterring innovation. Yet the pace of change in the industry is set only to increase, with biosimilars, digital developments, drug-device combinations already presenting new challenges, and the penetration of next generation technologies such as 3D printing, as well as the reality of real world data bringing increasing complexity in the future: What lies ahead for regulation of the industry and what innovations are we likely to see from the regulators in the future? With the additional requirements of Real World Data as a condition for access, will we see greater collaboration between regulators and Health Technology Agencies, and common methodologies for determining standards of evidence?

11:10 am - 11:40 amCan ‘Big Data’/RWD Cure the Life Sciences R&D Malaise?

Glen de Vries, President, Medidata  

‘Big data’ and the effective use of Real World Evidence in particular, has the potential to transform R&D. The collection and analysis of Real World Data can help identify potential new drug candidates, and promote their development into effective, approved and reimbursable products. It can also enhance the effectiveness of clinical trials through the identification of patients from specific sub populations, leading to potentially shorter and more effective trials. Yet many life science companies are failing to take full advantage of this new opportunity:  What is the potential for RWD/RWE to transform R&D? How can the challenges, to include integration of data and privacy concerns be addressed? What are the experiences and learnings to date? What does it mean for the future of clinical trials - will RCT remain the gold standard, or will real life trials become the principal standard for drug approval?

11:40 am - 12:10 pmInformation Technology as an Enabler of Excellence

David Venter, VP, Corporate, Commercial, & Supply Chain Capability Lead, GlaxoSmithKline
Pranit Kumar, Global Client Partner, Life Sciences, Wipro 

12:10 pm - 12:40 pmThe Global Health Economy and the Future

Professor Ian Goldin, Director, Oxford Martin School, University of Oxford

The advancement of the new frontiers of medical and life science technologies has unequivocal benefits in terms of  patient health and the growth prospects of the life science and health companies who will benefit from their commercialisation, but their adoption will likely accentuate the issue of affordability that is already challenging governments around the globe. Healthcare already account for some 19% of GDP expenditure in the US, and will account for an increasing share of budgets in the developing world as population size and demand for health services increases. How do we marry the need for innovation with the spectre of economic austerity and rising healthcare costs? Will we reach a point when pensions, personal care and government funded healthcare will be consigned to history? Where is the inflection point?

12:40 pm - 2:00 pmLunch
2:00 pm - 2:30 pmKeynote Interview

Joseph Jimenez, Chief Executive Officer, Novartis in conversation with Andrew Ward.

2:30 pm - 3:00 amHow Will Manufacturing and Supply Chain be Transformed?

Juan Andres, Head Global Technical Operations, Novartis Pharma AG
Heiner Hoppmann, Chief Executive Officer, Aenova Holding
Peter Grant, Chief Executive Officer, Skyepharma

Tectonic shifts in the life science business including globalisation, the rise of personalised medicine, a focus on biologics, and the delivery of health services closer to the patient have profound implications for the way life science products are manufactured and distributed in the future. Currently sub-optimised, manufacturing and the supply chain will be transformed to meet the new demands. However, the supply chain could also become a potential new source of profit in the future, and lead the life science company’s transformation from drug supplier to the provider of services to manage patient health. What is the vision for how drug manufacturing and the supply chain could be transformed? What innovations are we likely to see (for instance integration of supply chains across the drug, device and broader healthcare industry; micro-processing of drugs in pharmacies; 3D printing of drugs and devices at point of care)? Will life science companies become virtual manufacturers, outsourcing manufacturing and the supply chain? Will they embrace the challenge of supply chain leadership?

3:00 pm - 3:30 pmKeynote Address

Simon Stevens, Chief Executive, NHS England

3:30 pm - 3:45 pmFinancing the Future of the Global Pharmaceutical Industry - Opportunities, Risks, Mitigants

Philipp Gutzwiller, Global Head Healthcare, Global Corporates, Lloyds Bank Commercial Banking

As the global pharmaceutical market is undergoing rapid change, the options to finance future growth need to be fundamentally re-assessed. Slowing growth in developed markets coupled with higher levels of leverage and dividend pay-outs are shifting the paradigms of financial management across the industry. In addition, a growing exposure to emerging markets and the public sector, the return of strategic deal-making and the ongoing trend to outsource core processes require a review of risks and opportunities from a financing perspective.

3:45 pm - 4:15 pmThe CFO Perspective

Julie Brown, Chief Financial Officer, Smith & Nephew
Dominic Moorhead, Global Financial Controller, Takeda Pharmaceuticals
Peter Wilden, Chief Financial Officer and Executive Vice President, Ferring Pharmaceuticals

4:15 pm - 4:30 pmNetworking Coffee Break
4:30 pm - 4:50 pmKeynote

Tom Pike, Chief Executive Officer, Quintiles

4:50 pm - 5:40 pmThe Future of R&D: Exploring and Expanding the New Frontiers of Science

Glen de Vries, President, Medidata
Walter Capone, President, Multiple Myeloma Research Foundation
Dr Julie Gerberding, President, Vaccines, Merck Vaccines
Tom Pike, Chief Executive Officer, Quintiles
Dr John Reed, Head of Pharma Research & Early Development, Hoffmann La-Roche

As the industry continues in its quest to address productivity declines in its research efforts of recent years, how will the approaches to, the models and role of R&D within the life science companies be transformed? Will the industry succeed in significantly reducing the cost of producing and the time taken to launch new drugs? What will be the key to achieving that objective? Will we see increasing cross-industry collaboration-the sharing of knowledge and resources-in a bid to address critical innovation challenges? What form might such collaboration take (e.g. pre-competitive; partnerships/collaborations in high risk, high-cost areas of high unmet clinical need, multi-company consortia)? Beyond cancer, what are the new frontiers and which therapeutic and research areas hold the most promise for future success?  Will R&D remain the main source of value creation of life science companies?

5:40 pm - 5:45 pmClosing remarks from the Chair

8:15 am - 9:00 amRegistration and Refreshments
9:00 am - 9:05 am
9:05 am - 9:30 amKeynote Address

The Rt Hon George Freeman, Minister for Life Sciences UK

9:30 am - 10:30 amThe New Challengers? Emerging Markets

Christian Hogg, Chief Executive Officer, Hutchison China MediTech Limited
Wim Leereveld, Chief Executive Officer and Founder, Access to Medicine Foundation Index
Stefan Oschmann, Member of the Executive Board, CEO Pharma, Merck KGaA

Given the strength of the economic indicators, emerging markets will continue to play a central role in the strategies of life science companies.Yet emerging market companies are also now potential challengers. R&D, once the preserve of the developed markets, is gaining traction in emerging markets. No longer content with making only drug copies, they are trying their hand at innovation, and looking for new opportunities abroad, often with innovative models and approaches mastered from the necessity of serving price conscious consumers. Will we see an emerging markets company join the top 10 league of industry players by 2020? What models will emerging markets adopt? Which markets hold the greatest promise for future growth? Will the emerging markets remain principally volume driven? Will the IP battles between the developing and emerging markets be resolved?

10:30 am - 11:00 amNetworking Coffee Break
11:00 am - 12:00 amNavigating The Next Frontiers of Medicine: Opportunity and Challenge in the Convergence of Technology, Data and Healthcare

J.P Errico, Chairman, Founder, Principal Investor and CEO, electroCore
Kristoffer Famm, VP Bioelectronics R&D, GlaxoSmithKline
Daniel Mahony, Fund Manager-Healthcare, Polar Capital
Sandeep Raju, Vice President & Head of Life Sciences Europe, Wipro
Professor Christofer Toumazou, Founder and Chief Scientist, Institute of Biomedical Engineering, Imperial College, Chief Executive Officer, DNA Electronics

The future is arriving fast for the global life science industry as advanced technologies and materials, once considered the realm of science fiction, are now starting to emerge and are expected to play an ever larger part in the R&D efforts and product profile of life science companies as well as the transformation of the healthcare system. From 3D printers to wearable e-skins,to humanoid robotics and embedded sensors and beyond , the list of potential innovations - particularly when such technologies are matched with the computational power of computers and advanced data analytics - is vast, and the implications for the industry, for regulators, for patients, for payers and investors profound: How long before we see these innovations in use in clinical practice and the management of patient health? How readily will the healthcare system and life science companies adapt to these new technologies? Which technologies will have lasting impact?

12:00 am - 12:05 pmClosing remarks from the Chair